Ngā hua rapu - Stan Kaye
- E whakaatu ana i te 1 - 2 hua o te 2
-
1
Randomized Phase II Placebo-Controlled Trial of Maintenance Therapy Using the Oral Triple Angiokinase Inhibitor BIBF 1120 After Chemotherapy for Relapsed Ovarian Cancer mā Jonathan A. Ledermann, Allan Hackshaw, Stan Kaye, Gordon C. Jayson, Hani Gabra, Iain A. McNeish, Helena Earl, Timothy Perren, Martin Gore, Mojca Persic, Malcolm Adams, Lindsay E. James, Graham Temple, Michael Merger, Gordon Rustin
I whakaputaina 2011Artigo -
2
Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization mā Stéphanie Lheureux, Zhongwu Lai, Brian Dougherty, Sarah Runswick, Darren Hodgson, Kirsten M. Timms, Jerry S. Lanchbury, Stan Kaye, Charlie Gourley, David D.L. Bowtell, Elise C. Kohn, Clare L. Scott, Ursula A. Matulonis, Tony Panzarella, Katherine Karakasis, Julia V. Burnier, C. Blake Gilks, Mark J. O’Connor, Jane Robertson, Jonathan A. Ledermann, J. Carl Barrett, Tony W. Ho, Amit M. Oza
I whakaputaina 2017Artigo
Ngā utauta rapu:
Ngā marau whai pānga
Internal medicine
Medicine
Oncology
Adverse effect
Alternative medicine
BRCA mutation
Biology
Cancer
Cancer research
Chemotherapy
Confidence interval
Gastroenterology
Gene
Genetics
Hazard ratio
Olaparib
Ovarian cancer
PARP inhibitor
Pathology
Placebo
Poly ADP ribose polymerase
Polymerase
Serous ovarian cancer
Surgery